MetaCap

Enlivex (ENLV) vs Kairos Pharma (KAPA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kairos Pharma is the larger company by market cap ($2.0 million vs $2.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%KAPA-49.90%
+823%+364%-96%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%KAPA-46.21%
+633%+277%-79%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus KAPA key metrics
MetricENLVKAPA
Share price$1.05$0.4359
Market cap$2.01M$2.04M
1-day change-11.76%-4.62%
P/E ratio (TTM)0.00—
EPS (TTM)$7,904.00$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B$-5.45M
52-week high$434.40$7.28
52-week low$1.00$0.381
Distance from 52-week high-99.76%-94.01%
Analyst consensusnonenone
Avg. price target upside+7519.05%+11141.11%
Average volume73.14K364.25K
Shares outstanding1.91M4.69M
Employees341
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Kairos Pharma

KAPA stock →

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ENLV vs KAPA FAQ

Which is bigger, Enlivex or Kairos Pharma?

Kairos Pharma (KAPA) is larger, with a market capitalization of $2.04M compared with $2.01M for Enlivex (ENLV).

Are Enlivex and Kairos Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons